값20212022202320242025TTM판매비·일반관리비——————연구개발——————영업 이익——————비영업 수익, 합계——————이자비용(자본화한 이자 차감 후)——————이자비용을 제외한 비영업 수익——————비정상 수입/지출——————세전소득——————지분법 손익——————세금——————비지배 지분——————세후 기타 수익/비용——————중단된 사업 부문 제외 순이익——————중단된 사업——————순이익——————희석보정——————우선배당——————보통주주에게 귀속되는 희석 순이익——————주당 순이익(기본 EPS)——————희석 주당 순이익 (희석 EPS)——————평균 발행주식수——————희석주식수——————EBITDA——————EBIT——————매출원가——————기타 매출원가——————감가상각 및 무형자산 상각 (현금흐름)——————
Novo Nordisk A/S
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark.